var data={"title":"Acute generalized exanthematous pustulosis (AGEP)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Acute generalized exanthematous pustulosis (AGEP)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/contributors\" class=\"contributor contributor_credentials\">Chia-Yu Chu, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/contributors\" class=\"contributor contributor_credentials\">Jean-Claude Roujeau, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/contributors\" class=\"contributor contributor_credentials\">Maja Mockenhaupt, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 06, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H30350778\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute generalized exanthematous pustulosis (AGEP) is a rare, acute eruption characterized by the development of numerous nonfollicular sterile pustules on a background of edematous erythema (<a href=\"image.htm?imageKey=ALLRG%2F56807\" class=\"graphic graphic_picture graphicRef56807 \">picture 1A</a>) [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Fever and peripheral blood leukocytosis are usually present.</p><p>In approximately 90 percent of cases, AGEP is caused by drugs, most often antibiotics (eg, aminopenicillins and macrolides), antifungals, the calcium channel blocker <a href=\"topic.htm?path=diltiazem-drug-information\" class=\"drug drug_general\">diltiazem</a>, and antimalarials [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/3\" class=\"abstract_t\">3</a>]. The eruption develops within hours or days of drug exposure and resolves spontaneously in one to two weeks after drug discontinuation.</p><p>AGEP will be discussed in this topic. Other types of cutaneous drug reactions and pustular eruptions are discussed separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=drug-eruptions\" class=\"medical medical_review\">&quot;Drug eruptions&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=exanthematous-maculopapular-drug-eruption\" class=\"medical medical_review\">&quot;Exanthematous (maculopapular) drug eruption&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=lichenoid-drug-eruption-drug-induced-lichen-planus\" class=\"medical medical_review\">&quot;Lichenoid drug eruption (drug-induced lichen planus)&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=fixed-drug-eruption\" class=\"medical medical_review\">&quot;Fixed drug eruption&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">&quot;Drug reaction with eosinophilia and systemic symptoms (DRESS)&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae\" class=\"medical medical_review\">&quot;Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=approach-to-the-patient-with-pustular-skin-lesions\" class=\"medical medical_review\">&quot;Approach to the patient with pustular skin lesions&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H59808455\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A rough estimate of the incidence of AGEP is one to five per million per year [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/1,4-7\" class=\"abstract_t\">1,4-7</a>]. AGEP can occur at any age, although it most often affects adults. In a study including 97 validated cases of AGEP, the mean age was 56 years [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/7\" class=\"abstract_t\">7</a>]. Both sexes are affected, with a slight female predominance.</p><p class=\"headingAnchor\" id=\"H59809825\"><span class=\"h1\">ETIOLOGY AND PATHOGENESIS</span></p><p class=\"headingAnchor\" id=\"H1805080\"><span class=\"h2\">Eliciting factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>AGEP is caused by drugs in approximately 90 percent of cases [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/3\" class=\"abstract_t\">3</a>]. There are isolated reports of AGEP associated with viral, bacterial, or parasitic infections (eg, parvovirus B19, cytomegalovirus, coxsackie B4, <em>Mycoplasma pneumoniae)</em>; spider bites; and herbal medications [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/3,8-16\" class=\"abstract_t\">3,8-16</a>]. However, in some cases the cause remains undetermined.</p><p>Anti-infective agents (<a href=\"image.htm?imageKey=DERM%2F86916\" class=\"graphic graphic_table graphicRef86916 \">table 1A</a>), antimalarials, and the calcium channel blocker <a href=\"topic.htm?path=diltiazem-drug-information\" class=\"drug drug_general\">diltiazem</a> are the most frequently reported triggers of AGEP. In a multinational case-control study, pristinamycin, aminopenicillins, quinolones, <a href=\"topic.htm?path=hydroxychloroquine-drug-information\" class=\"drug drug_general\">hydroxychloroquine</a>, antibacterial sulfonamides, <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a>, and diltiazem&nbsp;were also strongly associated with the occurrence of AGEP [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/7\" class=\"abstract_t\">7</a>]. However, AGEP has been associated with a wide array of medications (<a href=\"image.htm?imageKey=DERM%2F86917\" class=\"graphic graphic_table graphicRef86917 \">table 1B</a>) [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"H1805087\"><span class=\"h2\">Immunologic mechanisms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathomechanism of AGEP has been only partially investigated. AGEP is a T cell mediated neutrophilic inflammation involving drug-specific CD4<sup>+</sup> T cells, cytotoxic CD8<sup>+</sup> T cells, and inflammatory cytokines and chemokines. Drug-specific CD4<sup>+</sup> T cells produce large amounts of CXCL8 and GM-CSF. CXCL8, a chemokine inducing neutrophil chemotaxis, and GM-CSF, which reduces neutrophil apoptosis, are both involved in tissue accumulation of neutrophils [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/18-24\" class=\"abstract_t\">18-24</a>]. T helper 17 (Th17) cells also may be involved in the recruitment, activation, and migration of neutrophils in AGEP [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/25,26\" class=\"abstract_t\">25,26</a>]. (See <a href=\"topic.htm?path=drug-allergy-pathogenesis#H20\" class=\"medical medical_review\">&quot;Drug allergy: Pathogenesis&quot;, section on 'IVd'</a>.)</p><p class=\"headingAnchor\" id=\"H75194816\"><span class=\"h2\">Genetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recessively inherited mutations in the&nbsp;<em>IL36RN</em>&nbsp;gene encoding the interleukin-36 receptor antagonist (IL-36Ra) have been found in generalized pustular psoriasis [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/27\" class=\"abstract_t\">27</a>]. These mutations in <em>IL36RN</em> lead to uncontrolled IL-36 signaling and enhanced production of proinflammatory cytokines IL-6, IL-8, IL-1alpha, and IL-1beta [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/27\" class=\"abstract_t\">27</a>]. Mutations in <em>IL36RN</em> have also been found in a very small subset of patients with AGEP (4 of 96 patients in one review) [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/28-30\" class=\"abstract_t\">28-30</a>]. This finding suggests that generalized pustular psoriasis and AGEP may share a common pathogenetic pathway, making it difficult in some cases to distinguish between the two entities. </p><p class=\"headingAnchor\" id=\"H59810120\"><span class=\"h1\">HISTOPATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The histologic hallmark of AGEP is a spongiform subcorneal <span class=\"nowrap\">and/or</span> intraepidermal pustules (<a href=\"image.htm?imageKey=DERM%2F86909%7EDERM%2F86910\" class=\"graphic graphic_picture graphicRef86909 graphicRef86910 \">picture 2A-B</a>). Other features include a marked edema of the papillary dermis, necrosis of single keratinocytes, and a superficial, interstitial, and mid-dermal inflammatory infiltrate of neutrophils with perivascular accentuation [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/31,32\" class=\"abstract_t\">31,32</a>]. Eosinophils are often seen in the pustules or dermis.</p><p class=\"headingAnchor\" id=\"H30350785\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>AGEP typically manifests with the rapid development of dozens to hundreds nonfollicular, sterile, pinhead-sized pustules on a background of edematous erythema with flexural accentuation (<a href=\"image.htm?imageKey=ALLRG%2F56807%7EDERM%2F86911%7EDERM%2F86912\" class=\"graphic graphic_picture graphicRef56807 graphicRef86911 graphicRef86912 \">picture 1A-C</a>) [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/1,2\" class=\"abstract_t\">1,2</a>]. The eruption usually occurs a few hours to a few days after the administration of the offending drug. In a series of 97 cases of AGEP, the median time between drug exposure and development of symptoms was one day for antibiotics and 11 days for all other drugs [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/7\" class=\"abstract_t\">7</a>].</p><p>The eruption generally begins on the face or intertriginous areas and rapidly extends to the trunk and limbs with a diffuse or patchy distribution. A localized variant also has been described [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/33-35\" class=\"abstract_t\">33-35</a>].</p><p>The pustular rash is occasionally accompanied by facial edema and nonspecific lesions such as purpura (especially on the legs), atypical target lesions, blisters, or vesicles. Severe cases of AGEP may present with atypical target lesions and coalescent pustules, resulting in superficial erosions and a clinical picture similar to Stevens-Johnson <span class=\"nowrap\">syndrome/toxic</span> epidermal necrolysis <span class=\"nowrap\">(SJS/TEN)</span> [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/36-42\" class=\"abstract_t\">36-42</a>]. Involvement of mucous membranes is unusual and, when present, is limited to erosions of the lips.</p><p>During the acute phase, fever above 38&deg;C (100.4&deg;F), leukocytosis with a neutrophil count <span class=\"nowrap\">&gt;7000/microL,</span> and mild eosinophilia are often present. Organ involvement is not common in AGEP, but can occur, particularly in older or compromised patients. A mild increase in serum transaminases or a reversible reduction in the creatinine clearance have been reported in some patients [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/1-3\" class=\"abstract_t\">1-3</a>]. </p><p>In a retrospective study of 58 patients with AGEP, 10 (17 percent) had evidence of at least one organ involvement [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/43\" class=\"abstract_t\">43</a>]. Liver <span class=\"nowrap\">and/or</span> kidney function tests were abnormal in seven patients, two developed acute respiratory distress, and one agranulocytosis. </p><p class=\"headingAnchor\" id=\"H59809179\"><span class=\"h1\">CLINICAL COURSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Skin symptoms usually resolve without treatment in one to two weeks after the discontinuation of the offending drug [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/44\" class=\"abstract_t\">44</a>]. The pustular eruption is followed by desquamation with characteristic collarettes of scale. Courses longer than two weeks are rare [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/45\" class=\"abstract_t\">45</a>]. Complications (eg, secondary skin infection, hypocalcemia) may occur in older or compromised patients [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/1-3,46\" class=\"abstract_t\">1-3,46</a>].</p><p class=\"headingAnchor\" id=\"H59810215\"><span class=\"h1\">DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H460065\"><span class=\"h2\">Clinical and histologic</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of AGEP is suspected in a patient presenting with an acute, febrile pustular eruption a few hours or days after starting a drug treatment, in particular antibiotics or <a href=\"topic.htm?path=diltiazem-drug-information\" class=\"drug drug_general\">diltiazem</a> (<a href=\"image.htm?imageKey=DERM%2F86916%7EDERM%2F86917\" class=\"graphic graphic_table graphicRef86916 graphicRef86917 \">table 1A-B</a>). Histologic examination of a skin biopsy is necessary to confirm the diagnosis and rule out other pustular eruptions. Gram staining of a pustular smear and culture of pustule exudate may be helpful in excluding a superficial skin infection. (See <a href=\"#H30350799\" class=\"local\">'Differential diagnosis'</a> below.)</p><p>Clinical and laboratory criteria for the diagnosis of AGEP are as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rapid development of a febrile (&ge;38&deg;C) pustular eruption a few hours or days after beginning a drug treatment</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical finding of dozens to hundreds of pinhead-sized, nonfollicular pustules on a background of edematous erythema (<a href=\"image.htm?imageKey=ALLRG%2F56807%7EDERM%2F86912%7EDERM%2F86911\" class=\"graphic graphic_picture graphicRef56807 graphicRef86912 graphicRef86911 \">picture 1A-C</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Leukocytosis with marked neutrophilia <span class=\"nowrap\">(&gt;7000/microL)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pustular smear and culture negative for bacteria</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rapid resolution of the rash after drug discontinuation</p><p/><p>Histologic features that support the diagnosis of AGEP include (<a href=\"image.htm?imageKey=DERM%2F86909%7EDERM%2F86910\" class=\"graphic graphic_picture graphicRef86909 graphicRef86910 \">picture 2A-B</a>) [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/47\" class=\"abstract_t\">47</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intra- or subcorneal spongiform pustules</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Eosinophils in the pustules or dermis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Necrotic keratinocytes</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Superficial, interstitial, and mid-dermal infiltrate rich in neutrophils</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Absence of tortuous, dilated blood vessels</p><p/><p>(See <a href=\"#H59810120\" class=\"local\">'Histopathology'</a> above.)</p><p class=\"headingAnchor\" id=\"H460080\"><span class=\"h2\">Laboratory tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patch testing with one or multiple suspected drugs may be useful in identifying the cause of AGEP [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/48-52\" class=\"abstract_t\">48-52</a>]. Patch testing is generally performed four to six weeks after the disease resolution. A positive test can confirm a suspected drug as the cause of AGEP. However, a negative result does not exclude that a certain drug is the causative agent. (See <a href=\"topic.htm?path=patch-testing#H26564848\" class=\"medical medical_review\">&quot;Patch testing&quot;, section on 'Patch test interpretation'</a>.)</p><p>A positive patch test reaction is often morphologically similar to AGEP, showing small sterile pustules on an erythematous base. Systemic reactions to patch testing rarely have been reported [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/52\" class=\"abstract_t\">52</a>].</p><p>Drug specific in vitro immunologic tests (eg, mast cell degranulation test, macrophage migration inhibition factor test, interferon gamma release test, lymphocyte proliferation response) are only performed in research settings [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/53-56\" class=\"abstract_t\">53-56</a>].</p><p class=\"headingAnchor\" id=\"H30350799\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of AGEP includes [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/1,2\" class=\"abstract_t\">1,2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Generalized acute pustular psoriasis (von Zumbusch type)</strong> &ndash; Seen at a single time point and without additional information, generalized acute pustular psoriasis and AGEP may be difficult to differentiate both clinically and histologically. Criteria that favor a diagnosis of generalized acute pustular psoriasis include a history of psoriasis; longer duration of fever and pustular eruption; absence of drug exposure; and histologic finding of subcorneal pustules with acanthosis and papillomatosis [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent1\">Although generalized acute pustular psoriasis can be elicited by drugs, the spectrum of medications known to trigger psoriasis (mainly beta-blockers or <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>) differs from the drugs associated with AGEP [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"topic.htm?path=pustular-psoriasis-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=subcorneal-pustular-dermatosis\" class=\"medical medical_review\">&quot;Subcorneal pustular dermatosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Stevens-Johnson <span class=\"nowrap\">syndrome/toxic</span> epidermal necrolysis</strong> &ndash; Severe cases of AGEP presenting with atypical target lesions and confluent pustules mimicking a positive Nikolsky sign may be difficult to differentiate from Stevens-Johnson <span class=\"nowrap\">syndrome/toxic</span> epidermal necrolysis <span class=\"nowrap\">(SJS/TEN)</span> [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/36-38,57\" class=\"abstract_t\">36-38,57</a>]. Features that favor a diagnosis of <span class=\"nowrap\">SJS/TEN</span> include: a longer latency between drug exposure and clinical manifestations (one to four weeks); involvement of the mucous membranes (in over 90 percent of cases); more severe course; and histologic finding of full thickness epidermal necrosis with a sparse inflammatory dermal infiltrate.</p><p/><p class=\"bulletIndent1\">There are isolated reports of overlap cases with clinical and histologic features of both AGEP and <span class=\"nowrap\">SJS/TEN</span> [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/39-41,58\" class=\"abstract_t\">39-41,58</a>]. (See <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Drug reaction with eosinophilia and systemic symptoms</strong> &ndash; Pustules can occasionally occur in patients with drug reaction with eosinophilia and systemic symptoms (DRESS). However, DRESS is characterized by a long latency (two to eight weeks) between drug exposure and appearance of symptoms, a more severe and prolonged clinical course than AGEP, eosinophilia or atypical lymphocytosis in the peripheral blood, and signs and symptoms of visceral involvement (abnormal liver function tests in approximately 80 percent of cases). The histology of DRESS is characterized by mild spongiosis with a lymphocytic infiltrate containing eosinophils in the superficial dermis. Cases with features of both DRESS and AGEP have been described [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/6,58-60\" class=\"abstract_t\">6,58-60</a>]. (See <a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">&quot;Drug reaction with eosinophilia and systemic symptoms (DRESS)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) </strong>&ndash; Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) is a rare, chronic, relapsing pustular eruption characterized by large, flaccid pustules that involve the trunk and the intertriginous areas (<a href=\"image.htm?imageKey=DERM%2F52552%7EDERM%2F71995\" class=\"graphic graphic_picture graphicRef52552 graphicRef71995 \">picture 3A-B</a>) [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/61\" class=\"abstract_t\">61</a>]. Sneddon-Wilkinson has been reported in association with pyoderma gangrenosum, monoclonal IgA gammopathy, IgA myeloma, and other lymphoproliferative diseases. On histology, there is a subcorneal accumulation of neutrophils without spongiosis or keratinocyte damage and a perivascular infiltrate of neutrophils (<a href=\"image.htm?imageKey=DERM%2F67144%7EDERM%2F79570\" class=\"graphic graphic_picture graphicRef67144 graphicRef79570 \">picture 4A-B</a>) [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/62-66\" class=\"abstract_t\">62-66</a>]. (See <a href=\"topic.htm?path=neutrophilic-dermatoses#H26\" class=\"medical medical_review\">&quot;Neutrophilic dermatoses&quot;, section on 'Subcorneal pustular dermatosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Bullous impetigo</strong> &ndash; Bullous impetigo generally occurs in young children. Small vesicles or pustules are usually localized to the head and neck or intertriginous areas (<a href=\"image.htm?imageKey=DERM%2F86956%7EOBGYN%2F63992\" class=\"graphic graphic_picture graphicRef86956 graphicRef63992 \">picture 5A-B</a>). Pustules rupture and leave erosions with a honey-colored crust (<a href=\"image.htm?imageKey=DERM%2F86957\" class=\"graphic graphic_picture graphicRef86957 \">picture 6</a>). Gram staining of pustule smear reveals Gram-positive cocci. Culture of pustule exudate is positive for <em>Staphylococcus aureus</em>. (See <a href=\"topic.htm?path=impetigo#H4\" class=\"medical medical_review\">&quot;Impetigo&quot;, section on 'Bullous impetigo'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H30350863\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>AGEP is a self-limiting disease with a favorable prognosis. Management includes withdrawal of the offending drug, supportive care, and symptomatic treatment of pruritus and skin inflammation.</p><p class=\"headingAnchor\" id=\"H1834480\"><span class=\"h2\">Drug withdrawal and supportive measures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prompt withdrawal of the causative agent is the mainstay treatment of AGEP. In patients taking multiple drugs, the drugs suspected to be the cause of AGEP (<a href=\"image.htm?imageKey=DERM%2F86916\" class=\"graphic graphic_table graphicRef86916 \">table 1A</a>) should be discontinued. Since re-exposure to the causative agent can induce another episode of AGEP, patients should be counseled to avoid the offending drug and be provided with a written list of the generic and brand names of the offending drug [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/67,68\" class=\"abstract_t\">67,68</a>].</p><p>Patients with severe forms of AGEP usually are hospitalized for treatment. Older or compromised patients with fever and widespread eruption may require fluid, electrolyte, and nutritional support.</p><p class=\"headingAnchor\" id=\"H1834487\"><span class=\"h2\">Symptomatic treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the pustular phase, moist dressings and antiseptic solutions may be used for relief of pruritus and prevention of bacterial superinfection. In the desquamation phase, emollients may be helpful in restoring the skin barrier function.</p><p>For symptomatic relief of pruritus and skin inflammation, we suggest topical rather than systemic corticosteroids. We use medium potency corticosteroids (group four (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 2</a>)). They are applied twice a day for one week.</p><p>The use of topical corticosteroids for AGEP has not been evaluated in clinical trials. Their use is based upon small case series and clinical experience of efficacy in other pruritic or inflammatory skin conditions [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/69,70\" class=\"abstract_t\">69,70</a>].</p><p>Given the natural history of rapid spontaneous resolution following withdrawal of the offending drug, we avoid systemic corticosteroids for the treatment of AGEP. In case series and case reports, systemic corticosteroids have been used to treat AGEP, but evidence that they shorten the disease course is lacking [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/16,44,69,71\" class=\"abstract_t\">16,44,69,71</a>].</p><p class=\"headingAnchor\" id=\"H459391\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>AGEP resolves spontaneously without sequelae in the majority of patients. Mortality rate of 2 percent has been reported in a pharmacovigilance study in France [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"H460153\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute generalized exanthematous pustulosis (AGEP) is a rare, acute eruption characterized by the development of numerous nonfollicular, sterile, small pustules on a background of edematous erythema (<a href=\"image.htm?imageKey=ALLRG%2F56807%7EDERM%2F86911%7EDERM%2F86912\" class=\"graphic graphic_picture graphicRef56807 graphicRef86911 graphicRef86912 \">picture 1A-C</a>) [<a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/1,2\" class=\"abstract_t\">1,2</a>]. In approximately 90 percent of cases, AGEP is caused by drugs, most often antibiotics, calcium channel blockers and antimalarials (<a href=\"image.htm?imageKey=DERM%2F86916%7EDERM%2F86917\" class=\"graphic graphic_table graphicRef86916 graphicRef86917 \">table 1A-B</a>). (See <a href=\"#H30350778\" class=\"local\">'Introduction'</a> above and <a href=\"#H1805080\" class=\"local\">'Eliciting factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fever above 38&deg;C (100.4&deg;F) and leukocytosis with a neutrophil count <span class=\"nowrap\">&gt;7000/microL</span> are usually present. The eruption resolves spontaneously in one to two weeks after the discontinuation of the offending drug. (See <a href=\"#H30350785\" class=\"local\">'Clinical features'</a> above and <a href=\"#H59809179\" class=\"local\">'Clinical course'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of AGEP is based upon the clinical presentation and histologic examination of a skin biopsy. The rapid resolution of the eruption after drug discontinuation also supports the diagnosis. (See <a href=\"#H59810215\" class=\"local\">'Diagnosis'</a> above and <a href=\"#H59810120\" class=\"local\">'Histopathology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prompt withdrawal of the causative agent is the mainstay of treatment of AGEP. Since re-exposure to the causative agent can induce another episode of AGEP, patients should be counseled to avoid the offending drug and be provided with a written list of the generic and brand names of the offending drug. (See <a href=\"#H1834480\" class=\"local\">'Drug withdrawal and supportive measures'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For symptomatic relief of pruritus and skin inflammation, we suggest topical corticosteroids (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We generally use medium potency topical corticosteroids (group four (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 2</a>)). They are applied twice a day for one week. (See <a href=\"#H1834487\" class=\"local\">'Symptomatic treatment'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H1198593676\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Alexis Sidoroff, MD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/1\" class=\"nounderline abstract_t\">Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol 2001; 28:113.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/2\" class=\"nounderline abstract_t\">Speeckaert MM, Speeckaert R, Lambert J, Brochez L. Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. Eur J Dermatol 2010; 20:425.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/3\" class=\"nounderline abstract_t\">Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991; 127:1333.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/4\" class=\"nounderline abstract_t\">Ji YZ, Geng L, Qu HM, et al. Acute generalized exanthematous pustulosis induced by docetaxel. Int J Dermatol 2011; 50:763.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/5\" class=\"nounderline abstract_t\">Nakamizo S, Kobayashi S, Usui T, et al. Clopidogrel-induced acute generalized exanthematous pustulosis with elevated Th17 cytokine levels as determined by a drug lymphocyte stimulation test. Br J Dermatol 2010; 162:1402.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/6\" class=\"nounderline abstract_t\">Son CH, Lee CU, Roh MS, et al. Acute generalized exanthematous pustulosis as a manifestation of carbamazepine hypersensitivity syndrome. J Investig Allergol Clin Immunol 2008; 18:461.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/7\" class=\"nounderline abstract_t\">Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007; 157:989.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/8\" class=\"nounderline abstract_t\">Birnie AJ, Litlewood SM. Acute generalized exanthematous pustulosis does not always have a drug-related cause. Br J Dermatol 2008; 159:492.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/9\" class=\"nounderline abstract_t\">Manzano S, Guggisberg D, Hammann C, Laubscher B. [Acute generalized exanthematous pustulosis: first case associated with a Chlamydia pneumoniae infection]. Arch Pediatr 2006; 13:1230.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/10\" class=\"nounderline abstract_t\">Ofuji S, Yamamoto O. Acute generalized exanthematous pustulosis associated with a human parvovirus B19 infection. J Dermatol 2007; 34:121.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/11\" class=\"nounderline abstract_t\">Cannistraci C, Parola IL, RiganO R, et al. Acute generalized exanthematous pustulosis in cystic echinococcosis: immunological characterization. Br J Dermatol 2003; 148:1245.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/12\" class=\"nounderline abstract_t\">Makris M, Spanoudaki N, Giannoula F, et al. Acute generalized exanthematous pustulosis (AGEP) triggered by a spider bite. Allergol Int 2009; 58:301.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/13\" class=\"nounderline abstract_t\">Davidovici BB, Pavel D, Cagnano E, et al. Acute generalized exanthematous pustulosis following a spider bite: report of 3 cases. J Am Acad Dermatol 2006; 55:525.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/14\" class=\"nounderline abstract_t\">Zaraa I, Ben Taazayet S, Trojjet S, et al. Acute generalized exanthematous pustulosis induced by the essential oil of Pistacia lentiscus. Clin Exp Dermatol 2012; 37:361.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/15\" class=\"nounderline abstract_t\">Yoon TY, Lee DY, Kim YJ, et al. Acute generalized exanthematous pustulosis induced by velvet antler. Br J Dermatol 2011; 165:447.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/16\" class=\"nounderline abstract_t\">Choi MJ, Kim HS, Park HJ, et al. Clinicopathologic manifestations of 36 korean patients with acute generalized exanthematous pustulosis: a case series and review of the literature. Ann Dermatol 2010; 22:163.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/17\" class=\"nounderline abstract_t\">Saissi EH, Beau-Salinas F, Jonville-B&eacute;ra AP, et al. [Drugs associated with acute generalized exanthematic pustulosis]. Ann Dermatol Venereol 2003; 130:612.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/18\" class=\"nounderline abstract_t\">Ueda T, Abe M, Okiyama R, et al. Acute generalized exanthematous pustulosis due to allylisopropylacetylurea: role of IL-17-producing T cells. Eur J Dermatol 2011; 21:140.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/19\" class=\"nounderline abstract_t\">Smith K, Norwood C, Skelton H. Do the physical and histologic features and time course in acute generalized exanthematous pustulosis reflect a pattern of cytokine dysregulation? J Cutan Med Surg 2003; 7:7.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/20\" class=\"nounderline abstract_t\">Britschgi M, Pichler WJ. Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Curr Opin Allergy Clin Immunol 2002; 2:325.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/21\" class=\"nounderline abstract_t\">Britschgi M, Steiner UC, Schmid S, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001; 107:1433.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/22\" class=\"nounderline abstract_t\">Britschgi M, von Greyerz S, Burkhart C, Pichler WJ. Molecular aspects of drug recognition by specific T cells. Curr Drug Targets 2003; 4:1.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/23\" class=\"nounderline abstract_t\">Pichler WJ. T cells in drug allergy. Curr Allergy Asthma Rep 2002; 2:9.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/24\" class=\"nounderline abstract_t\">Schmid S, Kuechler PC, Britschgi M, et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol 2002; 161:2079.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/25\" class=\"nounderline abstract_t\">Tokura Y, Mori T, Hino R. Psoriasis and other Th17-mediated skin diseases. J UOEH 2010; 32:317.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/26\" class=\"nounderline abstract_t\">Kabashima R, Sugita K, Sawada Y, et al. Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis. J Eur Acad Dermatol Venereol 2011; 25:485.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/27\" class=\"nounderline abstract_t\">Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011; 89:432.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/28\" class=\"nounderline abstract_t\">Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, et al. Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol 2013; 133:1904.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/29\" class=\"nounderline abstract_t\">Nakai N, Sugiura K, Akiyama M, Katoh N. Acute generalized exanthematous pustulosis caused by dihydrocodeine phosphate in a patient with psoriasis vulgaris and a heterozygous IL36RN mutation. JAMA Dermatol 2015; 151:311.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/30\" class=\"nounderline abstract_t\">Navarini AA, Simpson MA, Borradori L, et al. Homozygous missense mutation in IL36RN in generalized pustular dermatosis with intraoral involvement compatible with both AGEP and generalized pustular psoriasis. JAMA Dermatol 2015; 151:452.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/31\" class=\"nounderline abstract_t\">Burrows NP, Russell Jones RR. Pustular drug eruptions: a histopathological spectrum. Histopathology 1993; 22:569.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/32\" class=\"nounderline abstract_t\">Halevy S, Kardaun SH, Davidovici B, et al. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol 2010; 163:1245.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/33\" class=\"nounderline abstract_t\">Prange B, Marini A, Kalke A, et al. [Acute localized exanthematous pustulosis (ALEP)]. J Dtsch Dermatol Ges 2005; 3:210.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/34\" class=\"nounderline abstract_t\">Betto P, Germi L, Bonoldi E, Bertazzoni M. Acute localized exanthematous pustulosis (ALEP) caused by amoxicillin-clavulanic acid. Int J Dermatol 2008; 47:295.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/35\" class=\"nounderline abstract_t\">Rastogi S, Modi M, Dhawan V. Acute localized exanthematous pustulosis (ALEP) caused by Ibuprofen. A case report. Br J Oral Maxillofac Surg 2009; 47:132.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/36\" class=\"nounderline abstract_t\">Peermohamed S, Haber RM. Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: a case report and review of the literature. Arch Dermatol 2011; 147:697.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/37\" class=\"nounderline abstract_t\">Azib S, Florin V, Fourrier F, et al. Severe acute generalized exanthematous pustulosis with blistering mimicking toxic epidermal necrolysis, associated with a primary mumps infection. Clin Exp Dermatol 2014; 39:723.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/38\" class=\"nounderline abstract_t\">van Hattem S, Beerthuizen GI, Kardaun SH. Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature. Br J Dermatol 2014; 171:1539.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/39\" class=\"nounderline abstract_t\">Meiss F, Helmbold P, Meykadeh N, et al. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol 2007; 21:717.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/40\" class=\"nounderline abstract_t\">Kardaun SH. Acute generalized exanthematous pustulosis (AGEP), presenting with toxic epidermal necrolysis-like features, due to morphine: a neglected culprit? Eur J Dermatol 2011; 21:427.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/41\" class=\"nounderline abstract_t\">Wensween CA, Bouwes Bavinck JN. [Overlapping acute disseminated exanthematous pustulosis and toxic epidermal necrolysis]. Ned Tijdschr Geneeskd 2001; 145:1525.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/42\" class=\"nounderline abstract_t\">Kostopoulos TC, Krishna SM, Brinster NK, Ortega-Loayza AG. Acute generalized exanthematous pustulosis: atypical presentations and outcomes. J Eur Acad Dermatol Venereol 2015; 29:209.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/43\" class=\"nounderline abstract_t\">Hotz C, Valeyrie-Allanore L, Haddad C, et al. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol 2013; 169:1223.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/44\" class=\"nounderline abstract_t\">Alniemi DT, Wetter DA, Bridges AG, et al. Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996-2013. Int J Dermatol 2017; 56:405.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/45\" class=\"nounderline abstract_t\">Treudler R, Grunewald S, Gebhardt C, Simon JC. Prolonged course of acute generalized exanthematous pustulosis with liver involvement due to sensitization to amoxicillin and paracetamol. Acta Derm Venereol 2009; 89:314.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/46\" class=\"nounderline abstract_t\">Brandenburg VM, Kurts C, Eitner F, et al. Acute reversible renal failure in acute generalized exanthematous pustulosis. Nephrol Dial Transplant 2002; 17:1857.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/47\" class=\"nounderline abstract_t\">Kardaun SH, Kuiper H, Fidler V, Jonkman MF. The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis. J Cutan Pathol 2010; 37:1220.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/48\" class=\"nounderline abstract_t\">Friedmann PS, Ardern-Jones M. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol 2010; 10:291.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/49\" class=\"nounderline abstract_t\">Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005; 209:209.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/50\" class=\"nounderline abstract_t\">Whittam LR, Wakelin SH, Barker JN. Generalized pustular psoriasis or drug-induced toxic pustuloderma? The use of patch testing. Clin Exp Dermatol 2000; 25:122.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/51\" class=\"nounderline abstract_t\">Wolkenstein P, Chosidow O, Fl&eacute;chet ML, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996; 35:234.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/52\" class=\"nounderline abstract_t\">Mashiah J, Brenner S. A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch Dermatol 2003; 139:1181.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/53\" class=\"nounderline abstract_t\">Lazarov A, Livni E, Halevy S. Generalized pustular drug eruptions: confirmation by in vitro tests. J Eur Acad Dermatol Venereol 1998; 10:36.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/54\" class=\"nounderline abstract_t\">Halevy S, Cohen A, Livni E. Acute generalized exanthematous pustulosis associated with polysensitivity to paracetamol and bromhexine: the diagnostic role of in vitro interferon-gamma release test. Clin Exp Dermatol 2000; 25:652.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/55\" class=\"nounderline abstract_t\">Beltraminelli HS, Lerch M, Arnold A, et al. Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature. Br J Dermatol 2005; 152:780.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/56\" class=\"nounderline abstract_t\">Girardi M, Duncan KO, Tigelaar RE, et al. Cross-comparison of patch test and lymphocyte proliferation responses in patients with a history of acute generalized exanthematous pustulosis. Am J Dermatopathol 2005; 27:343.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/57\" class=\"nounderline abstract_t\">Natkunarajah J, Ostlere L. Severe acute generalized exanthematous pustulosis with blistering, mimicking toxic epidermal necrolysis. Clin Exp Dermatol 2012; 37:188.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/58\" class=\"nounderline abstract_t\">Bouvresse S, Valeyrie-Allanore L, Ortonne N, et al. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet J Rare Dis 2012; 7:72.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/59\" class=\"nounderline abstract_t\">Teo WL, Pang SM, Koh HY. Allopurinol hypersensitivity syndrome with acute generalized exanthematous pustulosis manifestations. Cutan Ocul Toxicol 2011; 30:243.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/60\" class=\"nounderline abstract_t\">Ben Salem C, Fathallah N, Saidi W, et al. Acute generalized exanthematous pustulosis as a manifestation of anticonvulsant hypersensitivity syndrome. Ann Pharmacother 2010; 44:1681.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/61\" class=\"nounderline abstract_t\">Cheng S, Edmonds E, Ben-Gashir M, Yu RC. Subcorneal pustular dermatosis: 50 years on. Clin Exp Dermatol 2008; 33:229.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/62\" class=\"nounderline abstract_t\">Kasha EE Jr, Epinette WW. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) in association with a monoclonal IgA gammopathy: a report and review of the literature. J Am Acad Dermatol 1988; 19:854.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/63\" class=\"nounderline abstract_t\">Butt A, Burge SM. Sneddon-Wilkinson disease in association with rheumatoid arthritis. Br J Dermatol 1995; 132:313.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/64\" class=\"nounderline abstract_t\">Brantley EI, Sheth P. Subcorneal pustular dermatosis in a patient with rheumatoid arthritis and diffuse scleroderma. Dermatol Online J 2009; 15:5.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/65\" class=\"nounderline abstract_t\">Ahmad K, Ramsay B. Pyoderma gangrenosum associated with subcorneal pustular dermatosis and IgA myeloma. Clin Exp Dermatol 2009; 34:46.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/66\" class=\"nounderline abstract_t\">Brown SJ, Barrett PD, Hendrick A, Langtry JA. Subcorneal pustular dermatosis in association with chronic lymphocytic leukaemia. Acta Derm Venereol 2003; 83:306.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/67\" class=\"nounderline abstract_t\">Gr&eacute;co M, Plantin P. Acute generalized exanthematous pustulosis (AGEP) induced by terbinafine with involuntary positive reintroduction. Eur J Dermatol 2005; 15:116.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/68\" class=\"nounderline abstract_t\">Park JJ, Yun SJ, Lee JB, et al. A case of hydroxychloroquine induced acute generalized exanthematous pustulosis confirmed by accidental oral provocation. Ann Dermatol 2010; 22:102.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/69\" class=\"nounderline abstract_t\">Lee HY, Chou D, Pang SM, Thirumoorthy T. Acute generalized exanthematous pustulosis: analysis of cases managed in a tertiary hospital in Singapore. Int J Dermatol 2010; 49:507.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/70\" class=\"nounderline abstract_t\">Ingen-Housz-Oro S, Hotz C, Valeyrie-Allanore L, et al. Acute generalized exanthematous pustulosis: a retrospective audit of practice between 1994 and 2011 at a single centre. Br J Dermatol 2015; 172:1455.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-generalized-exanthematous-pustulosis-agep/abstract/71\" class=\"nounderline abstract_t\">Chang SL, Huang YH, Yang CH, et al. Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia. Acta Derm Venereol 2008; 88:363.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15761 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H460153\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H30350778\" id=\"outline-link-H30350778\">INTRODUCTION</a></li><li><a href=\"#H59808455\" id=\"outline-link-H59808455\">EPIDEMIOLOGY</a></li><li><a href=\"#H59809825\" id=\"outline-link-H59809825\">ETIOLOGY AND PATHOGENESIS</a><ul><li><a href=\"#H1805080\" id=\"outline-link-H1805080\">Eliciting factors</a></li><li><a href=\"#H1805087\" id=\"outline-link-H1805087\">Immunologic mechanisms</a></li><li><a href=\"#H75194816\" id=\"outline-link-H75194816\">Genetics</a></li></ul></li><li><a href=\"#H59810120\" id=\"outline-link-H59810120\">HISTOPATHOLOGY</a></li><li><a href=\"#H30350785\" id=\"outline-link-H30350785\">CLINICAL FEATURES</a></li><li><a href=\"#H59809179\" id=\"outline-link-H59809179\">CLINICAL COURSE</a></li><li><a href=\"#H59810215\" id=\"outline-link-H59810215\">DIAGNOSIS</a><ul><li><a href=\"#H460065\" id=\"outline-link-H460065\">Clinical and histologic</a></li><li><a href=\"#H460080\" id=\"outline-link-H460080\">Laboratory tests</a></li></ul></li><li><a href=\"#H30350799\" id=\"outline-link-H30350799\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H30350863\" id=\"outline-link-H30350863\">MANAGEMENT</a><ul><li><a href=\"#H1834480\" id=\"outline-link-H1834480\">Drug withdrawal and supportive measures</a></li><li><a href=\"#H1834487\" id=\"outline-link-H1834487\">Symptomatic treatment</a></li></ul></li><li><a href=\"#H459391\" id=\"outline-link-H459391\">PROGNOSIS</a></li><li><a href=\"#H460153\" id=\"outline-link-H460153\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H1198593676\" id=\"outline-link-H1198593676\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/15761|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ALLRG/56807\" class=\"graphic graphic_picture\">- Acute generalized exanthematous pustulosis (AGEP)</a></li><li><a href=\"image.htm?imageKey=DERM/86909\" class=\"graphic graphic_picture\">- AGEP histo 1</a></li><li><a href=\"image.htm?imageKey=DERM/86910\" class=\"graphic graphic_picture\">- AGEP histo 2</a></li><li><a href=\"image.htm?imageKey=DERM/86911\" class=\"graphic graphic_picture\">- AGEP 1</a></li><li><a href=\"image.htm?imageKey=DERM/86912\" class=\"graphic graphic_picture\">- AGEP detail 2</a></li><li><a href=\"image.htm?imageKey=DERM/52552\" class=\"graphic graphic_picture\">- Subcorneal pustular dermatosis on back</a></li><li><a href=\"image.htm?imageKey=DERM/71995\" class=\"graphic graphic_picture\">- Subcorneal pustular dermatosis close view</a></li><li><a href=\"image.htm?imageKey=DERM/67144\" class=\"graphic graphic_picture\">- Subcorneal pustular dermatosis histopathology</a></li><li><a href=\"image.htm?imageKey=DERM/79570\" class=\"graphic graphic_picture\">- Subcorneal pustular dermatosis - histopathology</a></li><li><a href=\"image.htm?imageKey=DERM/86956\" class=\"graphic graphic_picture\">- Bullous impetigo 2</a></li><li><a href=\"image.htm?imageKey=OBGYN/63992\" class=\"graphic graphic_picture\">- Bullous impetigo</a></li><li><a href=\"image.htm?imageKey=DERM/86957\" class=\"graphic graphic_picture\">- Bullous impetigo crusts</a></li></ul></li><li><div id=\"DERM/15761|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/86916\" class=\"graphic graphic_table\">- AGEP inducing drugs 1</a></li><li><a href=\"image.htm?imageKey=DERM/86917\" class=\"graphic graphic_table\">- AGEP inducing drugs 2</a></li><li><a href=\"image.htm?imageKey=DERM/62402\" class=\"graphic graphic_table\">- Topical corticosteroids</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-pustular-skin-lesions\" class=\"medical medical_review\">Approach to the patient with pustular skin lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-allergy-pathogenesis\" class=\"medical medical_review\">Drug allergy: Pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-eruptions\" class=\"medical medical_review\">Drug eruptions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">Drug reaction with eosinophilia and systemic symptoms (DRESS)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=exanthematous-maculopapular-drug-eruption\" class=\"medical medical_review\">Exanthematous (maculopapular) drug eruption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fixed-drug-eruption\" class=\"medical medical_review\">Fixed drug eruption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=impetigo\" class=\"medical medical_review\">Impetigo</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lichenoid-drug-eruption-drug-induced-lichen-planus\" class=\"medical medical_review\">Lichenoid drug eruption (drug-induced lichen planus)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neutrophilic-dermatoses\" class=\"medical medical_review\">Neutrophilic dermatoses</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=patch-testing\" class=\"medical medical_review\">Patch testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pustular-psoriasis-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae\" class=\"medical medical_review\">Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=subcorneal-pustular-dermatosis\" class=\"medical medical_review\">Subcorneal pustular dermatosis</a></li></ul></div></div>","javascript":null}